Joel concentrates on corporate, commercial, securities, corporate governance, and mergers and acquisitions matters as well as strategic transactions and corporate structuring. He is a member of the firm’s Opinions Committee and a former member of the firm's Policy Committee.

He has extensive experience counseling high-technology businesses and the individuals creating them. He frequently guides acquisitions, collaborations, and licensing transactions in the life sciences industry. He frequently counsels boards of directors and their committees.

Joel has also functioned as counsel for several publicly and privately held companies in various industries, including media, software, packaged and consumer goods, apparel, financial, packaging, and real estate. In addition to guiding numerous domestic mergers, acquisitions, dispositions, and public offerings to successful conclusions, he has served as US counsel to several overseas firms in connection with establishing operations, their conduct of public offerings, and their acquisitions in the United States.

In the mergers and acquisitions area, Joel has led the acquisitions of public and private companies in media, marketing, apparel, life sciences, medical device, and other industries, and has represented numerous public and private sellers of entire enterprises, divisions, or subsidiaries. He has also been involved in acquiring businesses in Chapter 11 proceedings and has directed several corporate reorganizations.

He has served as counsel to many boards of directors and special committees, and advised investment bankers on a myriad of matters, including representing them in their roles as financial advisors and managing underwriters.

Joel is a frequent lecturer on topics such as underwriting public offerings of securities, corporate compliance, financings, acquiring and selling firms, fairness opinions, biotech-to-biotech acquisitions and dispositions, private placements, and legal opinion matters. Joel moderated the panel titled "Utilizing an Existing SPAC To Take Your Private Biotech Company Public" at the 2022 BIO International Convention. This panel covered what the next few years hold in store for SPACs looking to complete a merger and for those who have merged with private biotech companies.